{"disease":{"id":"non-metastatic-cancer","name":"non metastatic cancer"},"drugs":{"marketed":[{"drug_id":"darolutamide","indication_name":"Non-metastatic castration-resistant prostate cancer (nmCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."},{"drug_id":"chembl-chembl3183409","indication_name":"Non-metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"APALUTAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Androgen Receptor (AR)","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Apalutamide binds to the androgen receptor, blocking its function and reducing tumor growth."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06557967","title":"Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":22517,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT06835218","title":"PROCARE - PROstate Cancer Real World Evidence Registry","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"UroTrials Company (GmbH)","has_results":false},{"nct_id":"NCT05537922","title":"I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":2200,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05908799","title":"Emulation of the KEYNOTE-189 Trial Using Electronic Health Records","phase":"","overall_status":"COMPLETED","enrollment_count":1854,"lead_sponsor_name":"Aetion, Inc.","has_results":false},{"nct_id":"NCT06204302","title":"An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":1800,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07222566","title":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT02003924","title":"Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1401,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06013475","title":"An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings","phase":"","overall_status":"COMPLETED","enrollment_count":1375,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05362149","title":"An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings","phase":"","overall_status":"COMPLETED","enrollment_count":870,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02161900","title":"Randomized Controlled Trial Evaluating the Role of Exercise in Women Undergoing Treatment for Breast Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":850,"lead_sponsor_name":"Tata Memorial Hospital","has_results":false},{"nct_id":"NCT04613596","title":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":806,"lead_sponsor_name":"Mirati Therapeutics Inc.","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT06481813","title":"Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":730,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT03533127","title":"A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":648,"lead_sponsor_name":"Luye Pharma Group Ltd.","has_results":false},{"nct_id":"NCT06334120","title":"An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04205812","title":"Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":583,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT04623775","title":"A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":468,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT06416410","title":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":392,"lead_sponsor_name":"Allist Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03207867","title":"A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":315,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03956641","title":"Evolution of the Physical Condition in Treated Cancer Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Centre Paul Strauss","has_results":false},{"nct_id":"NCT04181060","title":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04697446","title":"External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":279,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT04619004","title":"HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":277,"lead_sponsor_name":"Daiichi Sankyo","has_results":true},{"nct_id":"NCT04925284","title":"Study of XB002 in Subjects With Solid Tumors (JEWEL-101)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":269,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06500455","title":"Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":269,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03829501","title":"A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":222,"lead_sponsor_name":"Kymab Limited","has_results":true},{"nct_id":"NCT02419495","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":221,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06060613","title":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":208,"lead_sponsor_name":"Obsidian Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03345810","title":"Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT03235765","title":"Cancer Panel From Blood of Lung Cancer Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT07326800","title":"Efficacy of the MAEva Program (Meditation, Acceptance, and Commitment to Values) Among Patients Treated For Breast Cancer.","phase":"NA","overall_status":"RECRUITING","enrollment_count":190,"lead_sponsor_name":"Institut de Cancérologie de Lorraine","has_results":false},{"nct_id":"NCT06784193","title":"Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Olema Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06022029","title":"A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"OncoNano Medicine, Inc.","has_results":false},{"nct_id":"NCT03761017","title":"MGD019 DART® Protein in Unresectable/Metastatic Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":162,"lead_sponsor_name":"MacroGenics","has_results":false},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT05364073","title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":160,"lead_sponsor_name":"ArriVent BioPharma, Inc.","has_results":false},{"nct_id":"NCT02376699","title":"Safety Study of SEA-CD40 in Cancer Patients","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT01655225","title":"A Study of LY3023414 in Participants With Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT04400656","title":"PROState Pathway Embedded Comparative Trial","phase":"","overall_status":"COMPLETED","enrollment_count":139,"lead_sponsor_name":"Imperial College London","has_results":true},{"nct_id":"NCT03674424","title":"Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"Jules Bordet Institute","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02245100","title":"Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":false},{"nct_id":"NCT03892096","title":"Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Cadex Genomics","has_results":false},{"nct_id":"NCT07140107","title":"Effectiveness of Original vs. AI-Generated Plain Language Summaries of Systematic Reviews","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":130,"lead_sponsor_name":"University of Split, School of Medicine","has_results":false},{"nct_id":"NCT03549000","title":"A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":127,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05538130","title":"A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT02498613","title":"A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":122,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}